Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lantheus Holdings, Inc. regarding potential breaches of fiduciary duties by certain officers and directors [1]. Group 1: Investigation Details - The investigation focuses on whether Lantheus Holdings' officers and directors made false statements or concealed information about the company's revenue outlook and growth potential [3]. - Allegations include that the company misrepresented its understanding of market dynamics, particularly regarding the sales growth potential and pricing of its product Pylarify [3]. Group 2: Shareholder Actions - Shareholders who purchased Lantheus Holdings shares prior to November 6, 2024, and still hold them can seek corporate reforms and the return of funds to the company at no cost [2][4]. - Interested shareholders are encouraged to contact Grabar Law Office for more information on the investigation and potential actions [2][4].

Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. for allegedly making false and misleading statements in its Offering Documents related to its September 2025 initial public offering [1][3]. Group 1: Allegations Against StubHub - The lawsuit claims that StubHub failed to disclose significant changes in the timing of payments to vendors, which adversely affected its free cash flow [3]. - It is alleged that these undisclosed changes rendered StubHub's free cash flow reports materially misleading [3]. - The complaint asserts that the positive statements made by StubHub regarding its business operations and prospects were materially false and lacked a reasonable basis due to the undisclosed issues [3]. Group 2: Legal Process and Participation - Investors in StubHub have until January 23, 2026, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff is defined as a representative party who acts on behalf of all class members and typically has the largest financial interest in the case [4]. - Investors can choose to remain absent from the proceedings without affecting their ability to share in any potential recovery [4].

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the lead plaintiff deadline on December 15, 2025 for a class action lawsuit [1] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the differences between Nanobodies and monoclonal antibodies, specifically about SLK and BIMZELX [5] - Key misleading claims include that SLK and BIMZELX share the same molecular targets, that SLK's Nanobody structure would not provide superior clinical benefits, and that its supposed tissue penetration would not lead to clinical efficacy [5] Legal Process - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [4][5]. Group 1: Legal Proceedings - Faruqi & Faruqi, LLP is investigating potential claims against Baxter and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions and risks to patient safety [4]. - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff [6]. Group 2: Financial Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries related to the Novum LVP but failed to take adequate remedial measures [4]. Group 3: Company Background - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in New York, Pennsylvania, California, and Georgia [3]. - The firm encourages anyone with information regarding Baxter's conduct to come forward, including whistleblowers and former employees [7].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Alexandria Real Estate is a real estate investment trust (REIT) focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Financial Performance - Alexandria Real Estate reported disappointing results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6]. Legal Proceedings - Investors have until January 26, 2026, to request to lead the class action case, which is pending in the U.S. District Court for the Central District of California [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand [5][6]. - Specific issues cited include incomplete training and onboarding at implanting centers, delayed software updates for claims processing, and existing excess inventory of older devices among customers [7]. Stock Performance - Following the announcement of an "elongated timeframe" for the Inspire V launch and a reduction in 2025 earnings per share guidance by over 80%, Inspire's stock price plummeted by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline in the Design IP segment to $425.9 million, a 7.7% year-over-year decrease, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the Q3 2025 results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The decline was attributed to revelations that Design IP customers required more customization, impacting the business model and economics of the Design IP segment [5][6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and experienced poor customer service leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride acknowledged that poor customer experience led to an estimated 10,000-15,000 fewer enrollments, resulting in a further stock drop of $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Freeport securities [3]. - Investors have until January 12, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Arizona [3]. Group 2: Company Operations and Safety Claims - Freeport operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [4][5]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [4]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - Following updates on September 24, 2025, regarding fatalities and expected lower sales, the stock fell by $7.69 per share (almost 17%) [7]. - Additional reports on September 25, 2025, regarding strained relations with the Indonesian government led to a further drop of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, indicated that the landslide was preventable, further impacting investor sentiment [9].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab, which led to a significant drop in stock price [1][2][6]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].